Significance needed on all endpoints

In some therapeutic settings the regulators require us to demonstrate effects in terms of two or more endpoints. For example, in asthma, we look for effects both in terms of lung function and symptoms. 

CPMP (2002) Note for Guidance on the Clinical Investigation of Medidnal Products in the Treatment of Asthma  

Under such circumstances no adjustment to the significance level is needed we have to show significance for both endpoints. 

---